Lista de obras -

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

artículo científico publicado en 2009

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

article by A Werzberger et al published 13 August 1992 in The New England Journal of Medicine

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment

artículo científico publicado en 2009

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

artículo científico publicado en 2005

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

artículo científico publicado en 2008

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma

artículo científico publicado en 2012

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

artículo científico publicado en 2007

Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age.

artículo científico publicado en 1994

Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210

artículo científico publicado en 2019

Attributes of potential utility in differentiating among "group H" streptococci or Streptococcus sanguis

artículo científico publicado en 1976

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

artículo científico publicado en 2005

Cellular location of streptolysin O ⬇️

artículo científico publicado el 1 de octubre de 1975

Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations

artículo científico publicado en 1993

Cross-resistance and imipenem.

artículo científico publicado en 1986

Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.

artículo científico publicado en 2013

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial

artículo científico publicado en 2016

Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.

artículo científico publicado en 1985

Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.

artículo científico publicado en 1985

Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics

scientific article published on 01 January 1987

Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients

scientific article published on 01 August 2007

Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma

artículo científico publicado en 2007

Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist

artículo científico publicado en 2004

Lysis and protoplast formation of group B streptococci by mutanolysin

artículo científico publicado en 1980

Membrane and cytoplasmic location of streptolysin S precursor.

artículo científico publicado en 1981

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

scientific article published on 10 July 2003

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

artículo científico publicado en 2009

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects.

artículo científico publicado en 2007

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

artículo científico publicado en 2007

Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers

artículo científico publicado en 2008

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

artículo científico publicado en 2009

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

artículo científico publicado en 2009

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation

artículo científico publicado en 2010

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

artículo científico publicado en 2010

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

artículo científico publicado en 2009

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

artículo científico publicado en 2009

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells

artículo científico publicado en 2013

Preparation of protoplasts of group H streptococci (Streptococcus sanguis) ⬇️

artículo científico publicado el 1 de enero de 1975

Problems and benefits of an antibiotic compassionate therapy program

artículo científico publicado en 1987

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

artículo científico publicado en 2009

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

artículo científico publicado en 2004

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

artículo científico publicado en 2008

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

artículo científico publicado en 2005

Relationship of cellular potential hemolysin in group A streptococci to extracellular streptolysin S.

artículo científico publicado en 1976

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

artículo científico publicado en 2009

Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin

artículo científico publicado en 1985

Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells

artículo científico publicado en 2005

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

artículo científico publicado en 2009

Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin

scientific article published on 01 December 1983

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A.

artículo científico publicado en 1992

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

artículo científico publicado en 2004

Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children.

artículo científico publicado en 1993

Streptolysin S activation by lipoteichoic acid

artículo científico publicado en 1981

Structure of eight streptococcal bacteriophages

artículo científico publicado en 1985

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

artículo científico publicado en 2009

The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.

artículo científico publicado en 2006

The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials

artículo científico publicado en 1988

The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients

scientific article published on 01 December 1986

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

artículo científico publicado en 2005

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

artículo científico publicado en 2009

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

artículo científico publicado en 1996

Lista de obras de

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age.

Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210

Attributes of potential utility in differentiating among "group H" streptococci or Streptococcus sanguis

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

Cellular location of streptolysin O ⬇️

Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations

Cross-resistance and imipenem.

Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial

Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.

Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.

Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics

Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients

Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma

Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist

Lysis and protoplast formation of group B streptococci by mutanolysin

Membrane and cytoplasmic location of streptolysin S precursor.

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects.

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells

Preparation of protoplasts of group H streptococci (Streptococcus sanguis) ⬇️

Problems and benefits of an antibiotic compassionate therapy program

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Relationship of cellular potential hemolysin in group A streptococci to extracellular streptolysin S.

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin

Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A.

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children.

Streptolysin S activation by lipoteichoic acid

Structure of eight streptococcal bacteriophages

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.

The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials

The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination